In multiple myeloma, bispecific CAR-T cells targeting BCMA and CS1 exhibited accelerated clearance of tumor cells in several mouse models when combined with a PD-1-blocking antibody [62]. This evidence concerns the gene TNFRSF17 and neoplasm.